For the quarter ending 2025-09-30, URGN made $27,482,000 in revenue. -$33,330,000 in net income. Net profit margin of -121.28%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 27,482,000 | 24,215,000 | 20,254,000 | 21,673,000 |
| Cost of revenue | 3,278,000 | 3,550,000 | 2,330,000 | 2,099,500 |
| Gross profit | 24,204,000 | 20,665,000 | 17,924,000 | 19,573,500 |
| Research and development expenses | 14,008,000 | 18,914,000 | 19,871,000 | 15,194,000 |
| Selling, general and administrative expenses | 37,582,000 | 43,199,000 | 34,967,000 | 31,078,500 |
| Operating loss | -27,386,000 | -41,448,000 | -36,914,000 | -26,699,000 |
| Financing on prepaid forward obligation | 4,621,000 | 4,644,000 | 4,583,000 | 5,861,500 |
| Interest expense on long-term debt | 3,373,000 | 4,132,000 | 4,068,000 | 3,169,500 |
| Interest and other income, net | 979,000 | 1,299,000 | 2,114,000 | 2,182,500 |
| Loss before income taxes | -34,401,000 | -48,925,000 | -43,451,000 | -33,547,500 |
| Income tax benefit (expense) | -1,054,000 | 1,015,000 | 392,000 | 1,351,500 |
| Net loss | -33,347,000 | -49,940,000 | -43,843,000 | -34,899,000 |
| Unrealized income (loss) on investments | 17,000 | -8,000 | -42,000 | -114,500 |
| Comprehensive loss | -33,330,000 | -49,948,000 | -43,885,000 | -35,013,500 |
| Basic and diluted loss per ordinary share (in dollars per share) | -0.69 | -1.05 | -0.92 | -0.75 |
| Weighted-average number of ordinary shares (in shares) | 48,057,386 | 47,739,816 | 47,422,119 | -18,522,707.5 |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)